This HTML5 document contains 77 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://linked.opendata.cz/resource/drugbank/drug/DB05246/identifier/national-drug-code-directory/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n23http://linked.opendata.cz/resource/drugbank/drug/DB05246/identifier/chemspider/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n12http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB05246/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/drug/DB05246/identifier/pharmgkb/
n10http://www.rxlist.com/cgi/generic/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/drug/DB05246/identifier/pubchem-compound/
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n25http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n11http://www.drugs.com/cdi/
n19http://linked.opendata.cz/resource/drugbank/drug/DB05246/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB05246/identifier/drugbank/
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB05246
rdf:type
n3:Drug
n3:description
Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin. [Wikipedia]
n3:dosage
n8:271B3ECB-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Hurst DL: Methsuximide therapy of juvenile myoclonic epilepsy. Seizure. 1996 Mar;5(1):47-50. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8777552 # Besag FM, Berry DJ, Pool F: Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction. Epilepsia. 2000 May;41(5):624-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10802770
n3:group
approved
n3:halfLife
1.4-2.6 hours for mesuximide and 28-38 hours for the active metabolite.
n3:indication
For the control of absence (petit mal) seizures that are refractory to other drugs.
owl:sameAs
n6:DB05246 n12:DB05246
dcterms:title
Methsuximide
adms:identifier
n16:0071-0525-24 n17:DB05246 n18:6476 n19:46505339 n21:PA164743145 n22:Methsuximide n23:6231
n3:mechanismOfAction
Binds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.
n3:packager
n20:271B3EC8-363D-11E5-9242-09173F13E4C5 n20:271B3EC6-363D-11E5-9242-09173F13E4C5 n20:271B3EC7-363D-11E5-9242-09173F13E4C5
n3:synonym
1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine Celontin 1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione Methsuximid Mesuximida N-methyl-alpha-methyl-alpha-phenylsuccinimide Alpha-methyl-alpha-phenyl n-methyl succinimide 1,3-Dimethyl-3-phenylsuccinimide Mesuximidum Alpha-methylphensuximide Metosuccimmide Metsuccimide N,2-Dimethyl-2-phenylsuccinimide (RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion Mesuximide 1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione
n3:toxicity
Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression. Levels greater than 40 µg/mL have caused toxicity and coma has been seen at levels of 150 µg/mL.
n3:foodInteraction
Take with food Avoid alcohol
n25:hasConcept
n26:M0263332
foaf:page
n10:methsuximide.htm n11:methsuximide.html
n3:IUPAC-Name
n4:271B3ED0-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3ED6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3ED5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3ED2-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3ED3-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3ED4-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3ECE-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3ECF-363D-11E5-9242-09173F13E4C5 n4:271B3ECC-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3ECD-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:N03AD03
n3:H-Bond-Acceptor-Count
n4:271B3EDC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3EDD-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3ED7-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3ED8-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3EDA-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3ED9-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3EDB-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
77-41-8
n3:category
n3:containedIn
n7:271B3EC9-363D-11E5-9242-09173F13E4C5 n7:271B3ECA-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B3EE2-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B3EE7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3EE4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3EE5-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B3EE6-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3EE1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3EE0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3EE3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3ED1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3EDE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3EDF-363D-11E5-9242-09173F13E4C5